Pub Date : 2024-09-28DOI: 10.1016/S0140-6736(24)01490-9
Nicholas Brink, Matthew F Chersich
{"title":"The Lancet Countdown on health and climate change: competing interests and optimism bias.","authors":"Nicholas Brink, Matthew F Chersich","doi":"10.1016/S0140-6736(24)01490-9","DOIUrl":"https://doi.org/10.1016/S0140-6736(24)01490-9","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"404 10459","pages":"1196"},"PeriodicalIF":98.4,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-28DOI: 10.1016/S0140-6736(24)01826-9
Curtis Marcoux, Pinkesh Thakkar, David M Conrad, Allam A Shawwa, Luke Y C Chen
{"title":"Bone marrow necrosis and hyperinflammation after treatment with inotuzumab ozogamicin for B-cell acute lymphoblastic leukaemia.","authors":"Curtis Marcoux, Pinkesh Thakkar, David M Conrad, Allam A Shawwa, Luke Y C Chen","doi":"10.1016/S0140-6736(24)01826-9","DOIUrl":"https://doi.org/10.1016/S0140-6736(24)01826-9","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"404 10459","pages":"1253-1254"},"PeriodicalIF":98.4,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-28DOI: 10.1016/S0140-6736(24)02130-5
Richard Horton
{"title":"Offline: Xenotransplantation-a new era beckons.","authors":"Richard Horton","doi":"10.1016/S0140-6736(24)02130-5","DOIUrl":"https://doi.org/10.1016/S0140-6736(24)02130-5","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"404 10459","pages":"1181"},"PeriodicalIF":98.4,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-28Epub Date: 2024-09-11DOI: 10.1016/S0140-6736(24)01754-9
Abi Beane, Manu Shankar-Hari
{"title":"Long-term ill health in sepsis survivors: an ignored health-care challenge?","authors":"Abi Beane, Manu Shankar-Hari","doi":"10.1016/S0140-6736(24)01754-9","DOIUrl":"10.1016/S0140-6736(24)01754-9","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":" ","pages":"1178-1180"},"PeriodicalIF":98.4,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-28Epub Date: 2024-09-12DOI: 10.1016/S0140-6736(24)01308-4
Børge G Nordestgaard, Anne Langsted
One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve stenosis due to high lipoprotein(a). Lipoprotein(a) concentrations are lowest in people from east Asia, Europe, and southeast Asia, intermediate in people from south Asia, the Middle East, and Latin America, and highest in people from Africa. Concentrations are more than 90% genetically determined and 17% higher in post-menopausal women than in men. Individuals at a higher cardiovascular risk should have lipoprotein(a) concentrations measured once in their lifetime to inform those with high concentrations to adhere to a healthy lifestyle and receive medication to lower other cardiovascular risk factors. With no approved drugs to lower lipoprotein(a) concentrations, it is promising that at least five drugs in development lower concentrations by 65-98%, with three currently being tested in large cardiovascular endpoint trials. This Review covers historical perspectives, physiology and pathophysiology, genetic evidence of causality, epidemiology, role in familial hypercholesterolaemia and diabetes, management, screening, diagnosis, measurement, prevention, and future lipoprotein(a)-lowering drugs.
{"title":"Lipoprotein(a) and cardiovascular disease.","authors":"Børge G Nordestgaard, Anne Langsted","doi":"10.1016/S0140-6736(24)01308-4","DOIUrl":"10.1016/S0140-6736(24)01308-4","url":null,"abstract":"<p><p>One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve stenosis due to high lipoprotein(a). Lipoprotein(a) concentrations are lowest in people from east Asia, Europe, and southeast Asia, intermediate in people from south Asia, the Middle East, and Latin America, and highest in people from Africa. Concentrations are more than 90% genetically determined and 17% higher in post-menopausal women than in men. Individuals at a higher cardiovascular risk should have lipoprotein(a) concentrations measured once in their lifetime to inform those with high concentrations to adhere to a healthy lifestyle and receive medication to lower other cardiovascular risk factors. With no approved drugs to lower lipoprotein(a) concentrations, it is promising that at least five drugs in development lower concentrations by 65-98%, with three currently being tested in large cardiovascular endpoint trials. This Review covers historical perspectives, physiology and pathophysiology, genetic evidence of causality, epidemiology, role in familial hypercholesterolaemia and diabetes, management, screening, diagnosis, measurement, prevention, and future lipoprotein(a)-lowering drugs.</p>","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":" ","pages":"1255-1264"},"PeriodicalIF":98.4,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号